Apart from the top 20 drug repurposing candidates with the highest predicted binding affinities to SARS-CoV-2 helicase, a significant number of our other hits listed in Supplementary Table also have published experimental validation of SARS-CoV-2 activity. Indeed, it is noteworthy that almost 30% of the drugs in our top 87 drug repurposing candidates have experimentally confirmed SARS-CoV-2 activity in vitro. While in vitro activity does not mean that all these drugs are operating by inhibiting the virus helicase or will have activity against the virus in vivo, this data shows that our computational screening method identified candidates that are highly enriched in compounds active against the virus. Our study suggests there is value in using in vitro assays to further screen the compounds in Supplementary Table that have not yet been tested, to potentially yield additional existing drugs with unrecognized activity against SARS-CoV-2. As they are already approved drugs, any promising candidates can be rapidly advanced to human trials.